相关实验视频

Updated: Jul 7, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

在复发性或耐火性多发性骨髓瘤中准BCMA的BiTE分子AMG420:一项1b期开放式扩展研究

Cesar Rodriguez1, Tulio Rodriguez2, Alain Kentos3

  • 1Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Leukemia & lymphoma
|July 21, 2025
PubMed
概括

两种特异性T细胞参与者AMG 420对多发性骨髓瘤显示有前途. 这种疗法证明了针对复发/耐药患者的BCMA的T细胞参与剂的概念验证.

关键词:
在B细胞成熟抗原.双特异性T细胞参与者.多发性骨髓瘤是多发性骨髓瘤的一种疾病.

更多相关视频

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K